Herzog Fox & Neeman‘s clients include global pharmaceutical companies, hospital spinouts and health maintenance organisations (HMOs), as well as insurers, investors and digital health innovators. The team is particularly experienced in regulatory matters, cross-border mandates, and health-tech collaborations and M&A. Dan Sharot advises on the life sciences, medical device and healthcare sectors at every growth stage; Neta Dorfman-Raviv assists HMOs and hospital clients with regulatory matters; and Zohar Yahalom is a former Medical Technologies Administration legal adviser. Orit Hipsher, Anat Gozlan Langberg and Tal Grofi also come recommended.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Sector knowledge
Testimonials
Collated independently by Legal 500 research team.
- ‘Knowledgeable and cooperative.’
- ‘A true strategic partner. The team is exceptional for its understanding of both the scientific and business aspects of clients’ work, especially in a field that is changing at a very high pace.’
- ‘They grasp the nuances of biotech R&D and AI platforms, and translate them into practical, forward-looking legal strategy.’
- ‘Their guidance on collaborations, licensing and IP is precise and commercially smart, and always aligned with growth stages and investor expectations.’
- ‘They’re agile, innovative, and highly responsive, using technology-enabled processes.’
- ‘They consistently anticipate clients’ needs and think several steps ahead - a rare combination that sets them apart from other firms.’
Key clients
- Accenture
- Adama
- AION Innovations Labs
- Alpha Omega
- Assuta Ashdod
- Assuta Medical Centers
- Ayrmid
- BMC Software
- BeeHero
- Biotic Circular Technologies
- Boston Scientific
- Cassidy Bio
Work highlights
Advised Qiagen on its acquisition of GNX Data Systems, a genomics platform, the matter addressing privacy, genetic data and health data reuse issues.
Advised AION Labs and its AI-driven biotech start-ups on licensing, data sharing, collaborations, financings, and research deals with Big Pharma and academic institutions.
Advised BioLineRx on an exclusive licence and equity deal with Ayrmid for FDA-approved APHEXDA®, the matter including IP, Innovation Authority grants, sub-licensing, and financing issues.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Neta Dorfman-Raviv; Dan Sharot; Zohar Yahalom; Orit Hipsher
Other key lawyers
Anat Gozlan Langberg; Tal Grofi; Lior Lederman